Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
about
Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases.Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis.Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
P2860
Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Determining an optimal clinica ...... led randomized clinical trial.
@en
Determining an optimal clinica ...... led randomized clinical trial.
@nl
type
label
Determining an optimal clinica ...... led randomized clinical trial.
@en
Determining an optimal clinica ...... led randomized clinical trial.
@nl
prefLabel
Determining an optimal clinica ...... led randomized clinical trial.
@en
Determining an optimal clinica ...... led randomized clinical trial.
@nl
P2860
P1476
Determining an optimal clinica ...... lled randomized clinical trial
@en
P2093
Mitsunori Seki
Shinya Taniguchi
P2860
P304
P356
10.1007/S00535-017-1383-5
P577
2017-08-24T00:00:00Z